Amisulpride Patent Expiration
Amisulpride is Used for prevention and treatment of post-operative nausea and vomiting. It was first introduced by Lxo Ireland Designated Activity Co
Amisulpride Patents
Given below is the list of patents protecting Amisulpride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Barhemsys | US11357753 | Rescue treatment of post operative nausea and vomiting | Feb 09, 2038 | Lxo Ireland |
| Barhemsys | US12005042 | Rescue treatment of post operative nausea and vomiting | Feb 09, 2038 | Lxo Ireland |
| Barhemsys | US12329740 | Rescue treatment of post operative nausea and vomiting | Feb 09, 2038 | Lxo Ireland |
| Barhemsys | US9084765 | Use of amisulpride as an anti-emetic | Feb 26, 2034 | Lxo Ireland |
| Barhemsys | US10525033 | Use of amisulpride as an anti-emetic | Mar 10, 2031 | Lxo Ireland |
| Barhemsys | US12194022 | Use of amisulpride as an anti-emetic | Mar 10, 2031 | Lxo Ireland |
| Barhemsys | US9545426 | Use of amisulpride as an anti-emetic | Mar 10, 2031 | Lxo Ireland |
| Barhemsys | US9889118 | Use of amisulpride as an anti-emetic | Mar 10, 2031 | Lxo Ireland |
Amisulpride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Amisulpride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery | Instituto do Cancer do Estado de São Paulo | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | LB Pharmaceuticals Inc. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |